HARROW, INC. (HROW) Latest Company News

Oct 5, 2026, 11:41 UTC
Harrow, Inc. and Viatris Inc. signed a side letter under which Viatris will pay tiered royalties on Japanese net sales of TYRVAYA and the parties will negotiate a collaboration for Viatris's R&D, manufacture and commercialization of TYRVAYA in Japan.
Oct 5, 2026, 11:41 UTC
Harrow, Inc. acquired the TYRVAYA rights in all countries except Japan from Viatris Inc. for $30.0 million in cash, with up to $70.0 million in contingent milestone payments.
Oct 5, 2026, 11:00 UTC
Harrow closed its acquisition of TYRVAYA, the first and only FDA-approved nasal spray for dry eye disease, adding a drop-free treatment option to its ocular surface franchise.
Source:
- globenewswire.com
Sep 30, 2026, 11:00 UTC
Harrow announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at the AAOpt Annual Meeting in Anaheim and the AAO Annual Meeting in New Orleans in October 2026.
Source:
- globenewswire.com
Sep 4, 2026, 20:48 UTC
Harrow, Inc. announced that Randall E. Pollard departed as Chief Accounting Officer and principal accounting officer, effective September 4, 2026, and appointed Andrew R. Boll as principal accounting officer, effective the same date.
Aug 21, 2026, 16:09 UTC
Harrow Inc. announced clinical study results showing its product Iheezo reduces eye-injection discomfort by more than half.
Source:
- benzinga.com
Aug 11, 2026, 01:07 UTC
Harrow reported a Q2 2026 loss of $0.34 per share, missing the Zacks Consensus Estimate of a loss of $0.23, and compared to earnings of $0.24 per share a year ago.
Source:
Jul 1, 2026, 11:00 UTC
Samsung Bioepis relaunched BYOOVIZ (ranibizumab-nuna) in the United States in partnership with Harrow.
Source:
- businesswire.com
- globenewswire.com
Jun 10, 2026, 11:00 UTC
Harrow re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for vernal keratoconjunctivitis in pediatric eyecare.
Source:

HROW

Harrow, Inc. and Viatris Inc. signed a side letter under which Viatris will pay tiered royalties on Japanese net sales of TYRVAYA and the parties will negotiate a collaboration for Viatris's R&D, manufacture and commercialization of TYRVAYA in Japan.

Harrow, Inc. acquired the TYRVAYA rights in all countries except Japan from Viatris Inc. for $30.0 million in cash, with up to $70.0 million in contingent milestone payments.

Harrow closed its acquisition of TYRVAYA, the first and only FDA-approved nasal spray for dry eye disease, adding a drop-free treatment option to its ocular surface franchise.

Harrow announced that 15 scientific abstracts featuring data from across its ophthalmic portfolio will be presented at the AAOpt Annual Meeting in Anaheim and the AAO Annual Meeting in New Orleans in October 2026.

Harrow, Inc. announced that Randall E. Pollard departed as Chief Accounting Officer and principal accounting officer, effective September 4, 2026, and appointed Andrew R. Boll as principal accounting officer, effective the same date.

Harrow Inc. announced clinical study results showing its product Iheezo reduces eye-injection discomfort by more than half.

Harrow reported a Q2 2026 loss of $0.34 per share, missing the Zacks Consensus Estimate of a loss of $0.23, and compared to earnings of $0.24 per share a year ago.

Samsung Bioepis relaunched BYOOVIZ (ranibizumab-nuna) in the United States in partnership with Harrow.

Harrow re-launched VERKAZIA (cyclosporine ophthalmic emulsion) 0.1% for vernal keratoconjunctivitis in pediatric eyecare.